Drug intelligence / Profile preview

Bovilis Bovipast RSP

Development stage: Unknown
Lead developer: Intervet
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

Bovilis Bovipast RSP is an inactivated injectable vaccine developed for cattle. It is designed to provide active immunization against Bovine Respiratory Disease (BRD) by targeting the Parainfluenza-3 virus, Bovine Respiratory Syncytial virus, and Mannheimia haemolytica serotype A1 and A6. The vaccine contains inactivated strains of these pathogens, along with adjuvants such as Aluminium hydroxide and Quil A, to stimulate the animal's immune response.

Brand names: Bovilis Bovipast RSP
Other names: Boviplas

Beyond the preview

Go deeper on Bovilis Bovipast RSP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bovilis Bovipast RSP.

Explore the full profile